Blood Glucose Testing a Significant Contributor to Pharmacy Costs in Patients Using Insulin

Web Exclusives - Conference Highlights ADA
Wayne Kuznar

San Diego, CA—Blood glucose testing constitutes more than 20% of US pharmacy costs in patients taking insulin, investigators from the IMS Consulting Group, Alexandria, VA, found in a study presented at the 2011 Scientific Sessions of the American Diabetes Association.

“New insulin regimens with simpler, user-friendly dosing options and simpler titration are warranted in order to enable relevant cost-savings,” the researchers stated.

Their study used medical and pharmacy claims data from 102 health plans across the United States. Included in their analysis were 74,936 patients with type 1 or type 2 diabetes with 2 or more prescriptions for insulin of any type, more than 6 months of continuous enrollment in their plan before study inclusion, and more than 12 months of continuous enrollment after study inclusion for outcomes measurement. Of the patients, 43.1% were new to insulin therapy.

Self-measured blood glucose constituted 20.0% ($602 of $2975) of the total annual diabetes-related pharmacy costs. The relative cost of self-measured blood glucose was 15.3% ($399 of $2607) for users of basal insulin only compared with 22.2% ($812 of $3666) for basal-bolus insulin users and 15.1% ($395 of $2617) for users of premixed insulin.

Related Items
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Conference Highlights ASH
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Emerging Therapies
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia
Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia
All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia
Last modified: February 14, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME